vosoritide
Selected indexed studies
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. (Lancet Child Adolesc Health, 2024) [PMID:37984383]
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. (Lancet, 2020) [PMID:32891212]
- Vosoritide: First Approval. (Drugs, 2021) [PMID:34694597]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. (2024) pubmed
- Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. (2020) pubmed
- Vosoritide: First Approval. (2021) pubmed
- Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. (2024) pubmed
- Vosoritide (Voxzogo) for Achondroplasia: A Review of Clinical and Real-World Evidence. (2025) pubmed
- International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. (2025) pubmed
- Vosoritide. (2012) pubmed
- Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. (2021) pubmed
- Sustained growth-promoting effects of vosoritide in children with achondroplasia from an ongoing phase 3 extension study. (2025) pubmed
- Vosoritide. (2022) pubmed